Bis-(3′,5′)-cyclic dimeric adenosine monophosphate: Strong Th1/Th2/Th17 promoting mucosal adjuvant

被引:112
作者
Ebensen, Thomas [1 ]
Libanova, Rimma [1 ]
Schulze, Kai [1 ]
Yevsa, Tetyana [1 ]
Morr, Michael [1 ]
Guzman, Carlos A. [1 ]
机构
[1] Helmholtz Ctr Infect Res, Dept Vaccinol & Appl Microbiol, D-38124 Braunschweig, Germany
关键词
Mucosal adjuvant; c-di-AMP; Intranasal administration; c-di-nucleotide; C-DI-GMP; TUMOR-NECROSIS-FACTOR; HIV-1 TAT PROTEIN; INTRANASAL VACCINATION; IMMUNE-RESPONSES; ALPHA-GALACTOSYLCERAMIDE; ACETOBACTER-XYLINUM; CELLULOSE SYNTHESIS; LIPOPEPTIDE MALP-2; ESCHERICHIA-COLI;
D O I
10.1016/j.vaccine.2011.05.026
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
New effective adjuvants are required to improve the performance of subunit vaccines. Here, we showed that bis-(3',5')-cyclic dimeric adenosine monophosphate (c-di-AMP), a second messenger molecule in bacteria and archaea, exerts strong adjuvant activities when delivered by mucosal route. In vitro studies showed that c-di-AMP was able to both stimulate pre-activated murine macrophages and promote the activation and maturation of dendritic cells of murine and human origin. Co-administration of c-di-AMP with beta-galactosidase (beta-Gal) by intranasal route to BALB/c mice resulted in the elicitation of significantly higher serum antigen-specific IgG titres than in controls. The induction of local immune responses was shown by the production of antigen-specific secretory IgA in different mucosal territories. In addition, strong cellular immune responses were observed against both the beta-Gal protein and a peptide encompassing its MHC class I-restricted epitope. The ratio of beta-Gal-specific antibodies and the secreted cytokine profiles by in vitro re-stimulated splenocytes suggested that a balanced Th1/Th2/Th17 response pattern is promoted by c-di-AMP. When C57BL/6 mice were immunized with OVA and c-di-AMP, vigorous in vivo CTL responses were also observed. These results indicated that c-di-AMP exhibits a high potential as adjuvant for the development of mucosal vaccines, in particular when cellular immunity is needed. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5210 / 5220
页数:11
相关论文
共 81 条
[1]  
Ågren LC, 1999, J IMMUNOL, V162, P2432
[2]   Features of bacterial cellulose synthesis in a mutant generated by disruption of the diguanylate cyclase 1 gene of Acetobacter xylinum BPR 2001 [J].
Bae, SO ;
Sugano, Y ;
Ohi, K ;
Shoda, M .
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2004, 65 (03) :315-322
[3]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[4]   Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements [J].
Barnden, MJ ;
Allison, J ;
Heath, WR ;
Carbone, FR .
IMMUNOLOGY AND CELL BIOLOGY, 1998, 76 (01) :34-40
[5]   Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant [J].
Borsutzky, S ;
Fiorelli, V ;
Ebensen, T ;
Tripiciano, A ;
Rharbaoui, F ;
Scoglio, A ;
Link, C ;
Nappi, F ;
Morr, M ;
Buttó, S ;
Cafaro, A ;
Mühlradt, PF ;
Ensoli, B ;
Guzmán, CA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (06) :1548-1556
[6]   Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant [J].
Borsutzky, S ;
Ebensen, T ;
Link, C ;
Becker, PD ;
Fiorelli, V ;
Cafaro, A ;
Ensoli, B ;
Guzmán, CA .
VACCINE, 2006, 24 (12) :2049-2056
[7]   Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults [J].
Boyce, TG ;
Hsu, HH ;
Sannella, EC ;
Coleman-Dockery, SD ;
Baylis, E ;
Zhu, YW ;
Barchfeld, O ;
DiFrancesco, A ;
Paranandi, M ;
Culley, B ;
Neuzil, KM ;
Wright, PF .
VACCINE, 2000, 19 (2-3) :217-226
[8]   Immunological foundations to the quest for new vaccine adjuvants [J].
Burdin, N ;
Guy, B ;
Moingeon, P .
BIODRUGS, 2004, 18 (02) :79-93
[9]  
Cao Shou-Chun, 2008, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V22, P174
[10]   Efficient immune responses against Intimin and EspB of enterohaernorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant [J].
Cataldi, Angel ;
Yevsa, Tetyana ;
Vilte, Daniel A. ;
Schulze, Kai ;
Castro-Parodi, Mauricio ;
Larzabal, Mariano ;
Ibarra, Cristina ;
Mercado, Elsa C. ;
Guzman, Carlos A. .
VACCINE, 2008, 26 (44) :5662-5667